U.S. researchers found that the drugs used to treat erectile dysfunction in the group of inhibitors of phosphodiesterase type 5 (PDE-5) penetration of anticancer drugs to ensure brain tumors in rats. Between blood and brain cancer is a biological barrier, similar to the blood-brain barrier (BBB) between blood and brain, the "filter" substances from the blood flow, and prevents the penetration of many drugs. However, in contrast to the blood-brain barrier, the barrier between the blood and the tumor is permeable by the action of PDE5 inhibitors, such as sildenafil ("Viagra"), tadalafil ("Cialis") and vardenafil ("Levitra") . To test the practical significance of this effect, the researchers looked at the medical center Tsedars-Sinai in Los Angeles, the effect of vardenafil and the cancer drug adriamycin in rats with brain tumors. Adriamycin was there for study because of its high efficiency and poor penetration through the barrier between the blood and tumor. Average duration of the animals in the control group were treated with placebo was 32 days in the group with only vardenafil - 35 days, only Adriamycin - 42 days and both the drug - 53 days. Slowing of tumor growth was proportional. In the study, we used a dose of vardenafil, the appropriate treatment of erectile dysfunction in men. In this case there are no side effects, and penetration of adriamycin in the healthy brain tissue. If the results are confirmed in humans, vardenafil will be included in the combination therapy of brain tumors.
No comments:
Post a Comment